|
|
Dividend Aristocrats
The blue-chip legacy payers
|
|
JNJJohnson & Johnson goes ex-dividend today — the 64th raise in motion
|
Today's the day. Johnson & Johnson goes ex-dividend at the open this morning on its $1.34 quarterly payment — payable June 9. If you own JNJ by yesterday's close, you collect the check. Buy today, and the next dividend gets paid by whoever sold you the shares. The new annual rate is $5.36, up 3.1% from $5.20. That marks the 64th consecutive year JNJ has raised the dividend. Read that number again. Sixty-four years.
The cash math behind the streak is what makes it durable. Q1 2026 sales hit $24.1 billion, up 9.9% year-over-year. Free cash flow was $1.5 billion in the quarter alone. The dividend has marched from $0.46 quarterly in 2008 to $1.34 today — that's about a 191% increase over 18 years, paid every single quarter through the financial crisis, two pandemics, and the Tylenol-talc litigation.
Yield is around 3.2% on a roughly $168 stock, so $10,000 = $320 a year. Paid quarterly. JNJ is one of only two U.S. companies that still hold an AAA credit rating from S&P — the other is Microsoft. That's the floor under this dividend.
Risk to know: pharma litigation never fully goes away. Talc cases have cost the company billions and aren't fully resolved. Stelara biosimilar competition is ramping. Medicare drug-price negotiation is the new variable. But the dividend isn't the question here. Even with $5 billion+ in legal reserves on the balance sheet, JNJ generates so much cash that the dividend's safety isn't in doubt. The pace of growth might slow. The payout stays.
|
|
Yield: 3.2%
|
$10K invested = $320/yr
|
Paid: Quarterly
|
|
|
|
PEPPepsiCo's 54th raise takes effect June 5 — and the stock is up 19% year-to-date
|
The other Aristocrat with a fresh check in motion. PepsiCo's board announced its 54th consecutive annualized dividend increase — a 4% raise — that takes effect with the June 5 ex-date and pays out shortly after. The new quarterly is $1.48 per share (up from $1.4225), annualized $5.92. The company plans to send $7.9 billion back to shareholders in dividends this year, plus a fresh $10 billion buyback authorization through February 2027.
Yield is about 4% on a $145 stock, so $10,000 = $400 a year. Paid quarterly. That's a higher yield than JNJ — and it reflects something interesting about where PepsiCo has been. Last spring, PEP was hovering near four-year lows on consumer-staples weakness and stagnant sales. The market pushed the yield up to 4.4% — unusually high for this name. The stock has since rallied 19% year-to-date in 2026 as Q1 results showed net revenue up 8.5% to $19.4 billion and core EPS up 5% in constant currency.
Risk to know: the payout ratio is sitting at about 90% of GAAP earnings. That's high. On a cash basis it's around 89%. Two raises in less than four months might look generous, but it leaves less cushion if North America beverage volumes soften. Frito-Lay margins have been pressured by health-trend headwinds for two years. The dividend itself is well-covered by free cash flow — PEP generated more than enough to fund the new $5.92 annualized rate. But the runway for raises is tighter than it was a decade ago. Pencil in 4-5% growth, not 8-10%.
|
|
Yield: 4.0%
|
$10K invested = $400/yr
|
Paid: Quarterly
|
|
|
|
|
|
Dividend Growth Stars
Fast-rising income builders
|
|
AAPLApple — biggest dividend payer in the world by dollars, with a 13% payout ratio
|
Apple is the largest dividend payer on the planet by total dollars sent to shareholders — but its yield is tiny because the stock keeps going up. Friday's close of $308.82 was an all-time high. Apple raised its quarterly dividend to $0.27 from $0.26 earlier this month, marking the 14th consecutive year of dividend increases. Annualized $1.08. Yield 0.35%, so $10,000 only buys you $35 a year.
The dollar amount per share is small. The total cash Apple ships is enormous — north of $15 billion annually just in dividends. That's because there are 15 billion shares outstanding. And here's the number that matters for whether the dividend keeps growing: the payout ratio is just 13%. Free cash flow per share is $6.61. The $1.08 dividend uses about 16% of free cash flow. That's enormous headroom — Apple could double the dividend tomorrow and still have a 26% payout ratio.
Why don't they? Because Apple's preferred method of returning cash is share buybacks — over $90 billion a year. Buybacks shrink the share count faster than the dividend grows the check, and they're more tax-efficient for shareholders.
Risk to know: AAPL trades around 35x earnings, which is rich for a hardware company. Services growth has been the bull thesis for several years; if Services growth slows or the App Store antitrust case reshapes margins, the multiple compresses. The dividend is not the question. The valuation is.
|
|
Yield: 0.35%
|
$10K invested = $35/yr
|
Paid: Quarterly
|
|
|
|
LLYEli Lilly — Mounjaro and Zepbound did $12.8B in Q1, and the dividend grew 15% a year
|
The fastest dividend grower in my Growth Stars rotation right now. Lilly's board declared a Q2 2026 dividend of $1.73 per share on May 4, payable June 10. That's annualized $6.92, up from $6.40 the year before — about an 8% raise. The 5-year dividend CAGR is roughly 15%. The streak: 12 consecutive years of increases.
The cash flow driving it is the GLP-1 explosion. Q1 2026 revenue grew 56% year-over-year to $19.8 billion. Mounjaro (diabetes) and Zepbound (obesity) combined for $12.8 billion in the quarter alone. EPS more than doubled to $8.55. Management raised full-year guidance to $82-85 billion in revenue and $35.50-$37.00 in EPS. The payout ratio sits at about 22% — extraordinary for a name growing this fast.
Yield is small — about 0.68% on a roughly $1,015 stock. $10,000 buys you about $68 a year in income today. But here's the magic with a 15%-CAGR dividend: if you'd bought $1,000 of LLY ten years ago and held, your yield on cost today is around 9%. The dividend grew 15% a year while you slept.
Risk to know: in late April, the FDA reported serious liver events in patients taking Foundayo — Lilly's new oral GLP-1 launched in April. Novo Nordisk is competing aggressively on price for the oral version. If safety or pricing pressure dents Mounjaro/Zepbound, the dividend growth rate compresses. At 30x earnings, the stock is priced for continued blockbuster execution. The current dividend is safe. The double-digit growth rate is what's at stake.
|
|
Yield: 0.68%
|
$10K invested = $68/yr
|
Paid: Quarterly
|
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Don't miss these ex-dates: JNJ TODAY ($1.34, pays June 9). HII Friday May 29 ($1.38, pays June 12). NVDA next Thursday June 4 ($0.25 — the post-25x-raise rate, pays June 26). PepsiCo's $1.48 quarterly ex-date is June 5. WY June 5 ($0.21 base). Five checks in motion over the next ten days.
|
|
I ran a screen this morning: the four picks today — JNJ, PEP, AAPL, LLY — sorted by 5-year dividend growth rate. LLY 15%. AAPL ~5%. PEP ~7%. JNJ ~5%. The 15% number jumps off the page, but watch this: at LLY's growth rate, the dividend doubles every five years. At JNJ's growth rate, it doubles every fourteen years. Same idea — yield on cost compounding — wildly different math. That's the most important variable in long-haul dividend investing.
|
|
Someone asked me: "If I had to pick just one of these four for the next 20 years, which would it be?" Honest answer — it depends on what you need. For maximum current income, PEP at 4%. For maximum dividend growth, LLY at 15% CAGR (with the most risk). For the safest combination of yield, growth, and balance sheet, JNJ — one of only two AAA-rated U.S. companies, 64 years of raises. For the lowest current yield but most balance-sheet optionality, Apple. There's no single right answer. I own JNJ and a little Apple. I don't own LLY because the valuation makes me pause. That's me. Your situation is yours.
|
|
|
|
The Dispatch
|
|
Four names this morning. Johnson & Johnson going ex-dividend today on the 64th raise. PepsiCo's 54th raise in motion for June 5. Apple at 14 years and a 13% payout ratio. Eli Lilly growing the dividend 15% a year on the back of a GLP-1 franchise that did $12.8 billion in Q1 alone. Tomorrow we head somewhere stranger — The Weird Yield is back, plus two more High Yield picks. See you in the morning.
|
|
— Charlie
|
|
|
|